Carregant...
Vitreoretinal interface abnormalities in patients treatedwith ranibizumab for diabetic macular oedema
PURPOSE: Intravitreal anti-vascular endothelial growth factor (VEGF) agents are effective in the treatment of central involving diabetic macular oedema (DMO). Vitreoretinal interface abnormalities (VRIA) are common in patients with DMO, and the effect of these on the response to anti-VEGF treatment...
Guardat en:
| Publicat a: | Graefes Arch Clin Exp Ophthalmol |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Springer Berlin Heidelberg
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5364245/ https://ncbi.nlm.nih.gov/pubmed/27957600 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00417-016-3562-0 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|